BioArctic combines a 9% Leqembi royalty engine, validated BrainTransporter optionality and a strong balance sheet, but premium valuation and product concentration create asymmetric execution risk.
Overview
BioArctic is a Swedish clinical-stage and commercial-stage biopharmaceutical company focused on disease-modifying therapies for Alzheimer’s disease, Parkinson’s disease, ALS and MSA. Its most valuable asset is Leqembi, marketed by Eisai and approved in 53 countries. BioArctic receives a 9% global net-sales royalty with no global Alzheimer’s R&D or commercialization cost liability, creating a capital-light, high-margin model. Q2 2026 net revenue was SEK 247.5 million, 10.5% above consensus, including SEK 179.4 million of Leqembi royalties, up 10.4% year over year. Gross margin was 94.13%, although operating expenses rose 20.2% to SEK 232.0 million as R&D represented 75% of costs. The company reported a SEK 6.5 million operating loss but maintained guidance for full-year 2026 profitability. **The balance sheet is a major support**, with SEK 1,990.0 million of cash and investments at quarter-end, more than SEK 2.30 billion after a USD 30 million Lilly upfront payment, zero debt and a 6.54x current ratio. **The central catalyst is Leqembi Iqlik**, which offers weekly at-home administration and could defend share against Kisunla. Valuation is demanding at 137.8x normalized P/E and 25.98x P/S, making execution and royalty growth critical.